Akouos, Inc. (AKUS)
Stock Price:
$21.70 USD
0.00 (0.00%)
Updated Jul 15, 2020 4:00 PM EDT - Market open
Pre-market: $21.61 -0.09 (-0.42%) Jul 15, 9:01 AM
Key Info
| Market Cap |
704.85M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
28.32M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 15, 2020 |
| Last Price |
$21.70 |
| Previous Close |
$21.70 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
21.32 - 22.41 |
| Day's Volume |
0 |
| 52-Week Range |
19.72 - 24.08 |
More Stats
| Market Cap |
704.85M |
| Enterprise Value |
597.23M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.32M |
| Float |
553,861 |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
77,536 |
| Short Ratio |
0.06 |
| Short % of Float |
0.32% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.00 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
107.62M |
| Net Cash / Share |
3.31 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -23.88 | -7.42 |
| Net Income | -25.74 | -6.01 |
| Shares Outstanding | 0.61 | 0.47 |
| Earnings Per Share | -42.49 | -12.84 |
| Operating Cash Flow | -19.51 | -6.74 |
| Capital Expenditures | -3.44 | -0.53 |
| Free Cash Flow | -22.95 | -7.27 |
| Cash & Equivalents | 26.40 | 24.34 |
| Total Debt | 13.78 | - |
| Net Cash / Debt | 12.61 | 24.34 |
| Assets | 45.16 | 25.78 |
| Liabilities | 19.27 | 5.36 |
| Book Value | -32.80 | -7.23 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Akouos, Inc. |
| Country |
United States |
| Employees |
54 |
| CEO |
Emmanuel J. Simons |
Stock Information
| Ticker Symbol |
AKUS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AKUS |
| IPO Date |
June 26, 2020 |
Description
Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.